Hillstream announces initial results from pembrolizumab, HSB-1216 combination

Hillstream BioPharma announced initial results evaluating the synergy of HSB-1216 with immune checkpoint inhibitors in KRAS G12C-mutated non-small cell lung cancer cells, Calu-1, with Pembrolizumab, an anti-PD-1 antibody. The study demonstrated significantly greater tumor inhibition of Calu-1 cells, when grown with human PBMCs and treated with HSB-1216 and Pembrolizumab. "We are greatly encouraged by the initial results showing crosstalk and synergy between an established and validated immuno-oncology pathway, anti-PD-1, and Ferroptosis, a new emerging iron-dependent cell death pathway and mechanism of action for HSB-1216," said Randy Milby, Hillstream’s CEO.